Light AI Launches New Zealand Field Study for Strep A Screening Platform
Event summary
- Light AI Inc. announced a company-funded field study in New Zealand for its QuickScan™ Strep A platform on June 15, 2026.
- The study, conducted with the National Hauora Coalition, evaluates real-world implementation in community and school-based healthcare settings.
- QuickScan™ Strep A aims to provide point-of-care screening and clinical decision support for Group A Streptococcus infections.
- Pre-FDA validation studies showed the algorithm achieved 96.57% accuracy and a 100% Negative Predictive Value.
The big picture
Light AI's field study in New Zealand represents a strategic move to validate its AI-powered diagnostic platform in real-world settings, addressing a global healthcare challenge with significant economic impact. The collaboration with the National Hauora Coalition underscores the potential for AI-driven solutions to improve access to care in underserved communities. Success here could position Light AI as a key player in the rapidly evolving digital diagnostics space.
What we're watching
- Regulatory Pathways
- Whether Light AI can navigate New Zealand's regulatory landscape to secure commercial deployment agreements.
- Market Expansion
- The pace at which Light AI can replicate this model in other international markets beyond New Zealand.
- Operational Integration
- How seamlessly QuickScan™ Strep A integrates into existing healthcare workflows in community settings.
Related topics